Volume 150, Issue 1, Pages e10 (January 2016)

Slides:

Advertisements

Similar presentations

Publication stage: In Press Accepted Manuscript

Advertisements

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg- positive chronic hepatitis B virus infection: a randomised, double-blind,

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up Willem P. Brouwer, Henry Lik-Yuen Chan,

Volume 149, Issue 6, Pages (November 2015)

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B Hye Soo Kim, Beom Kyung Kim,

Volume 137, Issue 3, Pages e1 (September 2009)

Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in e Antigen–Negative.

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg- positive chronic hepatitis B virus infection: a randomised, double-blind,

Volume 140, Issue 1, Pages (January 2011)

Volume 146, Issue 5, Pages (May 2014)

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Effectiveness of Hepatitis B Treatment in Clinical Practice

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 149, Issue 4, Pages e1 (October 2015)

Volume 146, Issue 1, Pages e5 (January 2014)

Rana Sabbagh, Edi Levi, Fadi Antaki Gastroenterology

Volume 154, Issue 1, Pages e6 (January 2018)

Volume 138, Issue 2, Pages e1 (February 2010)

Volume 140, Issue 2, Pages e1 (February 2011)

Unusual Case of an Upset Stomach

Sang Pyo Lee, Hang Lak Lee, Kang Nyeong Lee Gastroenterology

Volume 131, Issue 6, Pages (December 2006)

Volume 135, Issue 4, Pages (October 2008)

Volume 133, Issue 5, Pages (November 2007)

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive.

Volume 150, Issue 4, Pages (April 2016)

Volume 154, Issue 4, Pages (March 2018)

Volume 135, Issue 2, Pages (August 2008)

Volume 155, Issue 5, Pages e2 (November 2018)

Volume 139, Issue 4, Pages e3 (October 2010)

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B Jeong Han Kim, So Young Kwon, Young Sok.

Volume 152, Issue 1, Pages e4 (January 2017)

Volume 138, Issue 1, Pages (January 2010)

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay? Brian J. McMahon, MD, Brenna C. Simons, PhD Clinical.

Chronic Diarrhea With Hyperchloremic Acidosis and Hypokalemia

Volume 140, Issue 4, Pages e1 (April 2011)

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B Hye Soo Kim, Beom Kyung Kim,

Volume 66, Issue 1, Pages (January 2017)

Impact of New Hepatitis C Treatments in Different Regions of the World

Laura Rotundo, Sushil Ahlawat Gastroenterology

Volume 139, Issue 4, Pages e4 (October 2010)

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised,

Rafael Esteban, Maria Buti Gastroenterology

Volume 133, Issue 2, Pages (August 2007)

A Rare Cause of Gastrointestinal Bleeding in a Young Man

Volume 145, Issue 4, Pages e3 (October 2013)

Volume 148, Issue 3, Pages (March 2015)

Acute Bowel Obstruction in a Premenopausal Woman

Volume 136, Issue 7, Pages e4 (June 2009)

Jeremy P. Dwyer, Patrick Hosking, John Lubel Gastroenterology

Clinical Gastroenterology and Hepatology

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up Willem P. Brouwer, Henry Lik-Yuen Chan,

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Covering the Cover Gastroenterology

Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo Barjesh Chander Sharma, Praveen.

Volume 156, Issue 1, Pages 7-10 (January 2019)

An Unusual Hepatic Mass With Mixed Cystic-Solid Components in a Woman

Volume 156, Issue 4, Pages (March 2019)

Pao-Ying Lin, Horng-Yuan Lou, Chun-Chao Chang Gastroenterology

Volume 156, Issue 3, Pages (February 2019)

Volume 155, Issue 6, Pages (December 2018)

Volume 139, Issue 6, Pages e1 (December 2010)

A Palpable Mass in a Young Man With Chronic Lower Abdominal Pain

Young Chul Kim, Yong Eun Chung, Joon Seok Lim Gastroenterology

Electronic Clinical Challenges and Images in GI

The Future of Endoscopic Retrograde Cholangiopancreatography

A Female Patient With Persistent Epigastric Pain for 1 Week

A Rare Tumor of the Liver With a Sudden Presentation

Presentation transcript:

Volume 150, Issue 1, Pages 134-144.e10 (January 2016) Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, Florin A. Caruntu, Won Young Tak, Magdy Elkashab, Wan-Long Chuang, Seng-Gee Lim, Fehmi Tabak, Rajiv Mehta, Joerg Petersen, Graham R. Foster, Lillian Lou, Eduardo B. Martins, Phillip Dinh, Lanjia Lin, Amoreena Corsa, Prista Charuworn, G. Mani Subramanian, Hans Reiser, Hendrick W. Reesink, Scott Fung, Simone I. Strasser, Huy Trinh, Maria Buti, Giovanni B. Gaeta, Aric J. Hui, George Papatheodoridis, Robert Flisiak, Henry L.Y. Chan Gastroenterology Volume 150, Issue 1, Pages 134-144.e10 (January 2016) DOI: 10.1053/j.gastro.2015.09.043 Copyright © 2016 AGA Institute Terms and Conditions

Figure 1 Effect of TDF and peginterferon as combination or monotherapy on HBsAg loss. The rate of HBsAg loss in group A was significantly higher than rates for groups C (P < .001) or D (P=.003), as well as group B (unadjusted P < .001). The rate of HBsAg loss in group B did not significantly differ from that of groups C (P = .466) or group D (P = .883). Gastroenterology 2016 150, 134-144.e10DOI: (10.1053/j.gastro.2015.09.043) Copyright © 2016 AGA Institute Terms and Conditions

Figure 2 On-treatment HBsAg decline from baseline to week 48. Data shown are mean ± 95% CIs. Group A vs group B, P < .001; group A vs group C, P < .001; group A vs D, P = .016. Gastroenterology 2016 150, 134-144.e10DOI: (10.1053/j.gastro.2015.09.043) Copyright © 2016 AGA Institute Terms and Conditions

Supplementary Figure 1 Patient disposition. ∗Eleven subjects were randomized but not dosed; 4 withdrew consent after randomization and reasons are not provided for the remaining 7. †The analyzed population represents patients included in the Kaplan−Meier estimate, the missing = failure analysis and the safety analysis. Gastroenterology 2016 150, 134-144.e10DOI: (10.1053/j.gastro.2015.09.043) Copyright © 2016 AGA Institute Terms and Conditions